Organization | First People's Hospital of Shangqiu

First People's Hospital of Shangqiu Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2015

NCT02621333

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

First People's Hospital of Shangqiu

Active Ingredients

Drugs in Phase 3 Trials (6)

arginine (2 trials)

furosemide (lasix) (1 trial)

glycyrrhizin (1 trial)

spironolactone (aldactone) (1 trial)

trimetazidine (2 trials)

vitamin c (1 trial)

Drugs in Phase 2 Trials (1)

cytokine induced killer cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Carcinoma, Hepatocellular (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 7